Lumigan Versus Cosopt

To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Open-angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Taustine Eye Center, Louisville, Kentucky, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

adults with a diagnosis of bilateral open-angle glaucoma including: primary, pigment dispersion or exfoliation in both eyes
on no therapy the intraocular pressure should be 22-29 mm Hg inclusive at the 8:00 AM measurement
visual acuity should be 20/200 or better in each eye

Exclusion criteria

historical failure to respond to topical beta-blockers in a clinically meaningful manner
any contraindication to study medications
any anticipated change, or modification in the 6 weeks prior to Visit 1, in systemic hypertensive therapy during the trial

Treatment and study plan

bimatoprost 0.03%

Drug

dorzolamide 2%/timolol maleate 0.5% fixed combination

Drug

Placebo

Drug

Sponsors and collaborators

Lead sponsor

Pharmaceutical Research Network

Other

Registry information

Important dates

Study start: 2006
Study completion: 2007
First posted: Jan 9, 2006
Registry last updated: Nov 19, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed